Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells $742,909.50 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann sold 26,067 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the transaction, the executive vice president now directly owns 108,137 shares of the company’s stock, valued at $3,081,904.50. This represents a 19.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Collegium Pharmaceutical Stock Down 3.0 %

Shares of NASDAQ:COLL opened at $28.91 on Friday. The company’s fifty day moving average is $30.78 and its 200-day moving average is $33.21. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The company has a market capitalization of $910.26 million, a PE ratio of 12.46 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on COLL. Piper Sandler cut their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in shares of Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after buying an additional 175,892 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical during the third quarter worth approximately $757,000. Barclays PLC grew its stake in shares of Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 45,291 shares during the last quarter. Sanctuary Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 10.7% in the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock valued at $695,000 after purchasing an additional 1,731 shares in the last quarter. Finally, FMR LLC lifted its holdings in Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after buying an additional 35,439 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.